177Lu-DOTATOC Clinical Trials

3 actively recruiting trials

Pipeline

Early 1: 1Phase 2: 1Phase 3: 1

Top Sponsors

University Hospital, Basel, Switzerland1
Lund University Hospital1
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1

Indications

Cancer3
Neuroendocrine Tumors2
Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)1
Neuroendocrine Neoplasia's (NENs)1
Paraganglioma1

Other3 trials

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

Phase 2

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Early 1

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.